ACST Stock – (NASDAQ: ACST) is actually giving an update on the use
As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or the “Company”) ACST Stock (NASDAQ: ACST – TSX-V: ACST) is giving an update on the usage of the “at the market” equity of its providing plan.
As previously disclosed, Acasti entered into an amended and restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to implement an “at-the market” equity offering program under which Acasti may well issue as well as promote from time to time the everyday shares of its having an aggregate offering price of up to seventy five dolars million in the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as necessary pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the final distributions reported on January 27, 2021, Acasti given an aggregate of 20,159,229 common shares (the “ATM Shares”) with the NASDAQ Stock Market for aggregate gross proceeds to the Company of US$21.7 zillion. The ATM Shares had been marketed at prevailing market costs averaging US$1.0747 per share. No securities had been marketed throughout the facilities of the TSXV or maybe, to the understanding of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S 3 (No. 333 239538) as made effective on July 7, 2020, and also the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate gross proceeds raised was paid to the Agents in connection with their services. As a result of the latest ATM sales, Acasti has a total of 200,119,659 common shares issued and superb as of March 5, 2021.
The additional capital raised has strengthened Acasti’s balance sheet and will deliver the Company with extra freedom in its continuous review process to check out and evaluate strategic alternatives.
Approximately Acasti – ACST Stock
Acasti is actually a biopharmaceutical innovator that has historically focused on the research, commercialization and development of prescription medications making use of OM3 fatty acids delivered both as free fatty acids as well as bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have extensive clinical proof of safety and efficacy for lowering triglycerides in patients with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being formulated for people with serious HTG.
Forward Looking Statements – ACST Stock
Statements in this press release that are not statements of current or historical truth constitute “forward looking information” within the meaning of Canadian securities laws as well as “forward looking statements” within the meaning of U.S. federal securities laws (collectively, “forward-looking statements”). Such forward-looking claims include known and unknown risks, uncertainties, as well as other unknown variables that could result in the particular outcomes of Acasti to be materially different from historical success or from any later outcomes expressed or implied by such forward-looking statements. In addition to statements which explicitly describe these kinds of risks as well as uncertainties, people are actually urged to look at statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or any other similar expressions to be uncertain and forward-looking. People are cautioned not to place undue reliance on these forward looking statements, which speak just as of the particular date of this particular press release. Forward-looking statements in that press release include, but are not limited to, statements or info concerning Acasti’s strategy, succeeding operations and the review of its of strategic options.
The forward-looking assertions contained in this press release are expressly qualified in the entirety of theirs by this cautionary declaration, the “Special Note Regarding Forward Looking Statements” section contained in Acasti’s newest annual report on Form 10-K and quarterly report on Form 10-Q, which are readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at giving www.sedar.com and also on the investor section of Acasti’s website at www.acastipharma.com. Most forward looking statements in this press release are manufactured as of the date of this press release.
ACST Stock – Acasti doesn’t undertake to update some such forward-looking statements whether as a direct result of info that is new , future events or perhaps otherwise, except as needed by law. The forward-looking assertions contained herein are also subject typically to risks and assumptions as well as uncertainties that are actually described from time to time in Acasti’s public securities filings with the Securities as well as The Canadian and exchange Commission securities commissions, like Acasti’s newest annual report on Form 10-K and quarterly report on Form 10 Q underneath the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is actually giving an update on the usage